MedTrace Logo

Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients

NCT01579253 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2012-12-18

No results posted yet for this study

Summary

Patients with recurrent glioblastoma who are planned to receive a second course of radiation are to be included into this monocentric cohort trial. Due to multiple pre-treatments simultaneous combined positron emission tomography (PET) with O-(2-\[18F\]fluoroethyl)-l-tyrosine (FET) as well as magnetic resonance imaging (MRI) is used for treatment planning and follow-up imaging as it allows for a better distinction between treatment-related changes and viable tumor tissue.

Conditions

  • Glioblastoma
  • Nervous System Neoplasms
  • Central Nervous System Neoplasms
  • Astrocytoma
  • Glioma
  • Neoplasms, Neuroepithelial
  • Neuroectodermal Tumors
  • Neoplasms by Histologic Type
  • Neoplasms, Nerve Tissue

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Maximilian Niyazi, MD, MSc · Ludwig-Maximilians - University of Munich

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01579253 on ClinicalTrials.gov